Actively hiring
Health Care
Medical Laboratories
Artificial Intelligence
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
DigitalDx Ventures
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Registers and programsofficial lists and records that name the company
| Legal entity | 20/20 Biolabs, Inc. | SEC Form D |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers

Early detection of cancer, liver disease and over 500 other diseases. Receive a personal health action plan with full body MRI and blood…

Hemetron develops the first at-home blood test that is accurate, quantitative and affordable.

Qvin is the first and only healthcare service to scientifically prove menstrual blood can test for relevant health information - like a lab…

THE WAY A LABORATORY SHOULD BE High Quality.Transparent. Affordable. Community Focused. Tribal Diagnostics is a full-service…

Rythm Health is an American company offering at-home blood tests, with its own laboratory handling sample testing, logistics, software…

Accuragen is a molecular diagnostics company working on next generation sequencing platforms for diagnostic tests and operating a clinical…
Overview
About Us. 20/20 BioLabs develops and commercializes cutting-edge, AI-powered laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases.
News
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026...
Read more
Report
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest Franchise Model
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest Franchise Model ...
Read more
Report
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest Revenue and Expanding Commercial Opportunity
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest Revenue and Expanding Commercial Opportunity...
Read more
Report
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management's Recent East Asia Business Development Tour
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management's Recent East Asia Business Development...
Read more
Report
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand...
Read more
Report
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress...
Read more
Report
USC inks licensing agreement for prostate cancer screening tool
The University of South Carolina has agreed to license an algorithm developed by a renowned cancer and nutritional epidemiologist to 20/20 BioLabs, a health sciences company that offers home cancer screening tests.
Read more
Report
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress...
Read more
Report
20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol "AIDX" Following 3 Consecutive Years of Sales Growth
20/20 BioLabs Debuts Trading on Nasdaq Under Ticker Symbol
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Gaithersburg
United States
HQ

DigitalDx Ventures 




